icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
Yna3cgtpMekYQpfD